{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:12:55Z","timestamp":1788541975090,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Suleyman Demirel University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kidney transplantation is the most effective treatment option for most patients with end-stage kidney disease due to reduced mortality, decreased cardiovascular events and increased quality of life compared to patients treated with dialysis. However, kidney transplantation is not devoid of both acute and chronic complications including mineral bone disorders (MBD) which are already present in patients with chronic kidney disease (CKD) before kidney transplantation. The natural history of MBD after kidney transplantation is variable and new markers are needed to define MBD after kidney transplantation. One of these promising molecules is sclerostin. The main action of sclerostin is to inhibit bone formation and mineralization by blocking osteoblast differentiation and function. In kidney transplant recipients (KTRs), various studies have shown that sclerostin is associated with graft function, bone parameters, vascular calcification, and arterial stiffness although non-uniformly. Furthermore, data for inhibition of sclerostin with monoclonal antibody romosozumab for treatment of osteoporosis is available for general population but not in KTRs which osteoporosis is highly prevalent. In this narrative review, we have summarized the studies investigating the change of sclerostin before and after kidney transplantation, the relationship between sclerostin and laboratory parameters, bone metabolism and vascular calcification in the context of kidney transplantation. We also pointed out the uncertainties, explained the causes of divergent findings and suggest further potential study topics regarding sclerostin in kidney transplantation.<\/jats:p>","DOI":"10.1007\/s00223-024-01261-w","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T11:02:15Z","timestamp":1722337335000},"page":"339-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-3657","authenticated-orcid":false,"given":"Baris","family":"Afsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengin Elsurer","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"10","key":"1261_CR1","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","volume":"11","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J (2011) Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11(10):2093\u20132109. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03686.x","journal-title":"Am J Transplant"},{"key":"1261_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041193","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Hansrivijit P, Leeaphorn N, Acharya P, Torres-Ortiz A, Kaewput W, Kovvuru K, Kanduri SR, Bathini T, Cheungpasitporn W (2020) Recent advances and clinical outcomes of kidney transplantation. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9041193","journal-title":"J Clin Med"},{"issue":"1","key":"1261_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KDIGO CKD\u2013MBD Update Work Group","year":"2017","unstructured":"KDIGO CKD\u2013MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl (2011)"},{"issue":"11","key":"1261_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945\u20131953. https:\/\/doi.org\/10.1038\/sj.ki.5000414","journal-title":"Kidney Int"},{"key":"1261_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11120849","author":"ML Mace","year":"2021","unstructured":"Mace ML, Egstrand S, Morevati M, Olgaard K, Lewin E (2021) New insights to the crosstalk between vascular and bone tissue in chronic kidney disease\u2013mineral and bone disorder. Metabolites. https:\/\/doi.org\/10.3390\/metabo11120849","journal-title":"Metabolites"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fmed.2018.00211","volume":"5","author":"C Vangala","year":"2018","unstructured":"Vangala C, Pan J, Cotton RT, Ramanathan V (2018) Mineral and bone disorders after kidney transplantation. Front Med (Lausanne) 5:211. https:\/\/doi.org\/10.3389\/fmed.2018.00211","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1261_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","volume":"7","author":"P Evenepoel","year":"2007","unstructured":"Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y (2007) Tertiary \u2018hyperphosphatoninism\u2019 accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7(5):1193\u20131200. https:\/\/doi.org\/10.1111\/j.1600-6143.2007.01753.x","journal-title":"Am J Transplant"},{"issue":"1","key":"1261_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11255-019-02290-3","volume":"52","author":"A Figurek","year":"2020","unstructured":"Figurek A, Rroji M, Spasovski G (2020) Sclerostin: a new biomarker of CKD\u2013MBD. Int Urol Nephrol 52(1):107\u2013113. https:\/\/doi.org\/10.1007\/s11255-019-02290-3","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"1261_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178637","volume":"12","author":"L Tartaglione","year":"2017","unstructured":"Tartaglione L, Pasquali M, Rotondi S, Muci ML, Leonangeli C, Farcomeni A, Fassino V, Mazzaferro S (2017) Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS ONE 12(5):e0178637. https:\/\/doi.org\/10.1371\/journal.pone.0178637","journal-title":"PLoS ONE"},{"key":"1261_CR10","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2019.0022","author":"H Basir","year":"2019","unstructured":"Basir H, Altunoren O, Erken E, Kilinc M, Sarisik FN, Isiktas S, Gungor O (2019) Relationship between osteoporosis and serum sclerostin levels in kidney transplant recipients. Exp Clin Transplant. https:\/\/doi.org\/10.6002\/ect.2019.0022","journal-title":"Exp Clin Transplant"},{"issue":"15","key":"1261_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003300","volume":"95","author":"BG Hsu","year":"2016","unstructured":"Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC (2016) Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients: a cross-sectional study. Medicine (Baltim) 95(15):e3300. https:\/\/doi.org\/10.1097\/md.0000000000003300","journal-title":"Medicine (Baltim)"},{"issue":"10","key":"1261_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1097\/tp.0000000000001311","volume":"100","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation 100(10):2188\u20132193. https:\/\/doi.org\/10.1097\/tp.0000000000001311","journal-title":"Transplantation"},{"key":"1261_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020457","author":"J Magalh\u00e3es","year":"2022","unstructured":"Magalh\u00e3es J, Quelhas-Santos J, Pereira L, Neto R, Castro-Ferreira I, Martins S, Fraz\u00e3o JM, Carvalho C (2022) Could bone biomarkers predict bone turnover after kidney transplantation? A proof-of-concept study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11020457","journal-title":"J Clin Med"},{"issue":"2","key":"1261_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00223-021-00910-8","volume":"110","author":"AC Ferreira","year":"2022","unstructured":"Ferreira AC, Cotovio P, Aires I, Mendes M, Navarro D, Silva C, Caeiro F, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2022) The role of bone volume, FGF23 and sclerostin in calcifications and mortality; a cohort study in CKD stage 5 patients. Calcif Tissue Int 110(2):215\u2013224. https:\/\/doi.org\/10.1007\/s00223-021-00910-8","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"1261_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40620-022-01563-y","volume":"36","author":"YP Wang","year":"2023","unstructured":"Wang YP, Sidib\u00e9 A, Fortier C, Desjardins MP, Ung RV, Kremer R, Agharazii M, Mac-Way F (2023) Wnt\/\u03b2-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients. J Nephrol 36(4):969\u2013978. https:\/\/doi.org\/10.1007\/s40620-022-01563-y","journal-title":"J Nephrol"},{"issue":"12","key":"1261_CR16","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1210\/jc.2015-3056","volume":"100","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100(12):4669\u20134676. https:\/\/doi.org\/10.1210\/jc.2015-3056","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1261_CR17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s40620-023-01732-7","volume":"36","author":"HB Koh","year":"2023","unstructured":"Koh HB, Ryu JH, Kim SS, Kim MG, Park JB, Kim CD, Kang KP, Ro H, Han SY, Huh KH, Yang J (2023) Association between sclerostin levels and vascular outcomes in kidney transplantation patients. J Nephrol 36(7):2091\u20132109. https:\/\/doi.org\/10.1007\/s40620-023-01732-7","journal-title":"J Nephrol"},{"issue":"12","key":"1261_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s10157-020-01956-y","volume":"24","author":"S Zeng","year":"2020","unstructured":"Zeng S, Slowinski T, Pommer W, Hasan AA, Gaballa MMS, Lu Y, Kr\u00e4mer BK, Hocher B (2020) Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients. Clin Exp Nephrol 24(12):1177\u20131183. https:\/\/doi.org\/10.1007\/s10157-020-01956-y","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"1261_CR19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.nefro.2020.04.009","volume":"40","author":"M Coban","year":"2020","unstructured":"Coban M, Okten S (2020) The correlation between sclerostin and bone mineral density in renal transplant recipients. Nefrologia (Engl Ed) 40(5):506\u2013513. https:\/\/doi.org\/10.1016\/j.nefro.2020.04.009","journal-title":"Nefrologia (Engl Ed)"},{"issue":"6","key":"1261_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/tri.13888","volume":"34","author":"AC Ferreira","year":"2021","unstructured":"Ferreira AC, Mendes M, Silva C, Cotovio P, Aires I, Navarro D, Caeiro F, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2021) Bone densitometry versus bone histomorphometry in renal transplanted patients: a cross-sectional study. Transplant Int 34(6):1065\u20131073. https:\/\/doi.org\/10.1111\/tri.13888","journal-title":"Transplant Int"},{"issue":"5","key":"1261_CR21","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/ajt.13115","volume":"15","author":"JM Venner","year":"2015","unstructured":"Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF (2015) The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant 15(5):1336\u20131348. https:\/\/doi.org\/10.1111\/ajt.13115","journal-title":"Am J Transplant"},{"issue":"5","key":"1261_CR22","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1097\/tp.0000000000004099","volume":"106","author":"AC Ferreira","year":"2022","unstructured":"Ferreira AC, Mendes M, Silva C, Cotovio P, Aires I, Navarro D, Caeiro F, Ramos R, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2022) Improvement of mineral and bone disorders after renal transplantation. Transplantation 106(5):e251\u2013e261. https:\/\/doi.org\/10.1097\/tp.0000000000004099","journal-title":"Transplantation"},{"issue":"4","key":"1261_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000355781","volume":"39","author":"M Bonani","year":"2014","unstructured":"Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, W\u00fcthrich RP (2014) Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 39(4):230\u2013239. https:\/\/doi.org\/10.1159\/000355781","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"1261_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.kint.2018.12.024","volume":"95","author":"P Evenepoel","year":"2019","unstructured":"Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Pottel H, Cavalier E, Kuypers D (2019) Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 95(6):1461\u20131470. https:\/\/doi.org\/10.1016\/j.kint.2018.12.024","journal-title":"Kidney Int"},{"issue":"2","key":"1261_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1681\/asn.2018060656","volume":"30","author":"IDB Marques","year":"2019","unstructured":"Marques IDB, Ara\u00fajo M, Graciolli FG, Dos Reis LM, Pereira RMR, Alvarenga JC, Cust\u00f3dio MR, Jorgetti V, Elias RM, Moys\u00e9s RMA, David-Neto E (2019) A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol 30(2):355\u2013365. https:\/\/doi.org\/10.1681\/asn.2018060656","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1261_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ndt\/gfy129","volume":"34","author":"VM Brandenburg","year":"2019","unstructured":"Brandenburg VM, Verhulst A, Babler A, D\u2019Haese PC, Evenepoel P, Kaesler N (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34(3):408\u2013414. https:\/\/doi.org\/10.1093\/ndt\/gfy129","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1261_CR27","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1097\/tp.0000000000001312","volume":"100","author":"GJ Elder","year":"2016","unstructured":"Elder GJ (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism: who\u2019s conducting the orchestra? Transplantation 100(10):2016\u20132017. https:\/\/doi.org\/10.1097\/tp.0000000000001312","journal-title":"Transplantation"},{"issue":"10","key":"1261_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6(10):e25900. https:\/\/doi.org\/10.1371\/journal.pone.0025900","journal-title":"PLoS ONE"},{"issue":"9","key":"1261_CR29","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1073\/pnas.0408742102","volume":"102","author":"CN Bennett","year":"2005","unstructured":"Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102(9):3324\u20133329. https:\/\/doi.org\/10.1073\/pnas.0408742102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1261_CR30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.17219\/acem\/68739","volume":"26","author":"B Pietrzyk","year":"2017","unstructured":"Pietrzyk B, Smertka M, Chudek J (2017) Sclerostin: intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med 26(8):1283\u20131291. https:\/\/doi.org\/10.17219\/acem\/68739","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"1261_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2011-2152","volume":"97","author":"K Amrein","year":"2012","unstructured":"Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A (2012) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97(1):148\u2013154. https:\/\/doi.org\/10.1210\/jc.2011-2152","journal-title":"J Clin Endocrinol Metab"},{"key":"1261_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cca.2019.12.008","volume":"502","author":"A Bouquegneau","year":"2020","unstructured":"Bouquegneau A, Evenepoel P, Paquot F, Malaise O, Cavalier E, Delanaye P (2020) Sclerostin within the chronic kidney disease spectrum. Clin Chim Acta 502:84\u201390. https:\/\/doi.org\/10.1016\/j.cca.2019.12.008","journal-title":"Clin Chim Acta"},{"key":"1261_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2022.100433","author":"RC Riddle","year":"2023","unstructured":"Riddle RC (2023) Endocrine functions of sclerostin. Curr Opin Endocr Metab Res. https:\/\/doi.org\/10.1016\/j.coemr.2022.100433","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"1","key":"1261_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nefro.2015.07.006","volume":"36","author":"A Kirkpantur","year":"2016","unstructured":"Kirkpantur A, Balci M, Turkvatan A, Afsar B (2016) Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia 36(1):24\u201332. https:\/\/doi.org\/10.1016\/j.nefro.2015.07.006","journal-title":"Nefrologia"},{"issue":"6","key":"1261_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/ckj\/sfv077","volume":"8","author":"A Kirkpantur","year":"2015","unstructured":"Kirkpantur A, Balci M, Turkvatan A, Afsar B (2015) Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J 8(6):737\u2013743. https:\/\/doi.org\/10.1093\/ckj\/sfv077","journal-title":"Clin Kidney J"},{"issue":"8","key":"1261_CR36","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1055\/s-0043-112349","volume":"49","author":"A Mak\u00f3wka","year":"2017","unstructured":"Mak\u00f3wka A, G\u0142yda M, Majewska ER, Nowicki M (2017) Varying patterns of biomarkers of mineral and bone metabolism after kidney transplantation. Horm Metab Res 49(8):618\u2013624. https:\/\/doi.org\/10.1055\/s-0043-112349","journal-title":"Horm Metab Res"},{"issue":"5","key":"1261_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197994","volume":"13","author":"MJ Hernandez","year":"2018","unstructured":"Hernandez MJ, Dos Reis LM, Marques ID, Araujo MJ, Truyts CAM, Oliveira IB, Barreto FC, David-Neto E, Custodio MR, Moyses RM, Bellorin-Font E, Jorgetti V (2018) The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: a post hoc analysis. PLoS ONE 13(5):e0197994. https:\/\/doi.org\/10.1371\/journal.pone.0197994","journal-title":"PLoS ONE"},{"issue":"5","key":"1261_CR38","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2019.06.007","volume":"96","author":"M Ara\u00fajo","year":"2019","unstructured":"Ara\u00fajo M, Bacelar Marques ID, Graciolli FG, Fukuhara L, Machado Dos Reis L, Cust\u00f3dio M, Jorgetti V, Elias RM, David-Neto E, Moys\u00e9s RMA (2019) Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin. Kidney Int 96(5):1100\u20131104. https:\/\/doi.org\/10.1016\/j.kint.2019.06.007","journal-title":"Kidney Int"},{"issue":"4","key":"1261_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/ndt\/gfy306","volume":"35","author":"P Evenepoel","year":"2020","unstructured":"Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Cavalier E, Kuypers D (2020) Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol Dial Transplant 35(4):697\u2013705. https:\/\/doi.org\/10.1093\/ndt\/gfy306","journal-title":"Nephrol Dial Transplant"},{"issue":"48","key":"1261_CR40","doi-asserted-by":"publisher","first-page":"E5187","DOI":"10.1073\/pnas.1413828111","volume":"111","author":"MK Chang","year":"2014","unstructured":"Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M (2014) Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci USA 111(48):E5187-5195","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1261_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248\u2013255. https:\/\/doi.org\/10.1210\/jc.2013-2786","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1261_CR42","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/cjn.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8(5):819\u2013823. https:\/\/doi.org\/10.2215\/cjn.07670712","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1261_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1055\/s-0042-107791","volume":"48","author":"K Kakareko","year":"2016","unstructured":"Kakareko K, Rydzewska-Rosolowska A, Brzosko S, Gozdzikiewicz-Lapinska J, Koc-Zorawska E, Samocik P, Kozlowski R, Mysliwiec M, Naumnik B, Hryszko T (2016) Renal handling of sclerostin in response to acute glomerular filtration decline. Horm Metab Res 48(7):457\u2013461. https:\/\/doi.org\/10.1055\/s-0042-107791","journal-title":"Horm Metab Res"},{"issue":"6","key":"1261_CR44","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/jcb.20506","volume":"95","author":"NH Kulkarni","year":"2005","unstructured":"Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE (2005) Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95(6):1178\u20131190. https:\/\/doi.org\/10.1002\/jcb.20506","journal-title":"J Cell Biochem"},{"issue":"1","key":"1261_CR45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","volume":"57","author":"L Gifre","year":"2013","unstructured":"Gifre L, Ruiz-Gasp\u00e0 S, Monegal A, Nomdedeu B, Filella X, Gua\u00f1abens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57(1):272\u2013276. https:\/\/doi.org\/10.1016\/j.bone.2013.08.016","journal-title":"Bone"},{"key":"1261_CR46","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/boneres.2017.13","volume":"5","author":"EE Beier","year":"2017","unstructured":"Beier EE, Sheu TJ, Resseguie EA, Takahata M, Awad HA, Cory-Slechta DA, Puzas JE (2017) Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Res 5:17013. https:\/\/doi.org\/10.1038\/boneres.2017.13","journal-title":"Bone Res"},{"issue":"4","key":"1261_CR47","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00223-012-9684-4","volume":"92","author":"K Brabnikova Maresova","year":"2013","unstructured":"Brabnikova Maresova K, Pavelka K, Stepan JJ (2013) Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 92(4):354\u2013361. https:\/\/doi.org\/10.1007\/s00223-012-9684-4","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1261_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00223-018-0491-4","volume":"104","author":"H Boltenst\u00e5l","year":"2019","unstructured":"Boltenst\u00e5l H, Qureshi AR, Behets GJ, Lindholm B, Stenvinkel P, D\u2019Haese PC, Haarhaus M (2019) Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients. Calcif Tissue Int 104(2):214\u2013223. https:\/\/doi.org\/10.1007\/s00223-018-0491-4","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"1261_CR49","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T (2016) Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/sclerostin. J Bone Miner Res 31(10):1791\u20131802. https:\/\/doi.org\/10.1002\/jbmr.2869","journal-title":"J Bone Miner Res"},{"key":"1261_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122027","author":"A Mar\u00e9","year":"2019","unstructured":"Mar\u00e9 A, Verhulst A, Cavalier E, Delanaye P, Behets GJ, Meijers B, Kuypers D, D\u2019Haese PC, Evenepoel P (2019) Clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8122027","journal-title":"J Clin Med"},{"issue":"4","key":"1261_CR51","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2215\/cjn.0000000000000368","volume":"19","author":"HS J\u00f8rgensen","year":"2024","unstructured":"J\u00f8rgensen HS, Claes K, Smout D, Naesens M, Kuypers D, D\u2019Haese P, Cavalier E, Evenepoel P (2024) Associations of changes in bone turnover markers with change in bone mineral density in kidney transplant patients. Clin J Am Soc Nephrol 19(4):483\u2013493. https:\/\/doi.org\/10.2215\/cjn.0000000000000368","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1261_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jbmr.217","volume":"26","author":"UI M\u00f6dder","year":"2011","unstructured":"M\u00f6dder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26(2):373\u2013379. https:\/\/doi.org\/10.1002\/jbmr.217","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1261_CR53","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1210\/jc.2014-2372","volume":"99","author":"E Ishimura","year":"2014","unstructured":"Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M (2014) Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 99(11):4315\u20134320. https:\/\/doi.org\/10.1210\/jc.2014-2372","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1261_CR54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/ajkd.2000.8289","volume":"36","author":"RG Carlini","year":"2000","unstructured":"Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E (2000) Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 36(1):160\u2013166. https:\/\/doi.org\/10.1053\/ajkd.2000.8289","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1261_CR55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11255-018-2050-3","volume":"51","author":"B Pietrzyk","year":"2019","unstructured":"Pietrzyk B, Wyskida K, Ficek J, Kolonko A, Ficek R, Wi\u0119cek A, Olszanecka-Glinianowicz M, Chudek J (2019) Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. Int Urol Nephrol 51(3):519\u2013526. https:\/\/doi.org\/10.1007\/s11255-018-2050-3","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"1261_CR56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/jbmr.3923","volume":"35","author":"KA Carpenter","year":"2020","unstructured":"Carpenter KA, Ross RD (2020) Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice. J Bone Miner Res 35(3):596\u2013607. https:\/\/doi.org\/10.1002\/jbmr.3923","journal-title":"J Bone Miner Res"},{"key":"1261_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.967774","volume":"13","author":"T Michigami","year":"2022","unstructured":"Michigami T (2022) Roles of osteocytes in phosphate metabolism. Front Endocrinol (Lausanne) 13:967774. https:\/\/doi.org\/10.3389\/fendo.2022.967774","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1261_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00223-021-00823-6","volume":"109","author":"N Ito","year":"2021","unstructured":"Ito N, Prideaux M, Wijenayaka AR, Yang D, Ormsby RT, Bonewald LF, Atkins GJ (2021) Sclerostin directly stimulates osteocyte synthesis of fibroblast growth factor-23. Calcif Tissue Int 109(1):66\u201376. https:\/\/doi.org\/10.1007\/s00223-021-00823-6","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"1261_CR59","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O\u2019Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11):4577\u20134583. https:\/\/doi.org\/10.1210\/en.2005-0239","journal-title":"Endocrinology"},{"key":"1261_CR60","doi-asserted-by":"publisher","first-page":"1178166","DOI":"10.3389\/fendo.2023.1178166","volume":"14","author":"J Zuo","year":"2023","unstructured":"Zuo J, Hasan AA, Hocher CF, Kalk P, Kleuser B, Kr\u00e4mer BK, Hocher B (2023) Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients. Front Endocrinol (Lausanne) 14:1178166. https:\/\/doi.org\/10.3389\/fendo.2023.1178166","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"1261_CR61","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1073\/pnas.1221255110","volume":"110","author":"ZC Ryan","year":"2013","unstructured":"Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R (2013) Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 110(15):6199\u20136204. https:\/\/doi.org\/10.1073\/pnas.1221255110","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1261_CR62","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1006\/bbrc.2001.5084","volume":"284","author":"AE Bowe","year":"2001","unstructured":"Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284(4):977\u2013981. https:\/\/doi.org\/10.1006\/bbrc.2001.5084","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1261_CR63","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1038\/s41467-020-19155-4","volume":"11","author":"J Kim","year":"2020","unstructured":"Kim J, Han W, Park T, Kim EJ, Bang I, Lee HS, Jeong Y, Roh K, Kim J, Kim JS, Kang C, Seok C, Han JK, Choi HJ (2020) Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains. Nat Commun 11(1):5357. https:\/\/doi.org\/10.1038\/s41467-020-19155-4","journal-title":"Nat Commun"},{"issue":"2","key":"1261_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54(2):168\u2013178. https:\/\/doi.org\/10.1002\/jcph.239","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1261_CR65","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1210\/jc.2011-3419","volume":"97","author":"A Arasu","year":"2012","unstructured":"Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR (2012) Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 97(6):2027\u20132032. https:\/\/doi.org\/10.1210\/jc.2011-3419","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1261_CR66","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1002\/jbmr.1718","volume":"27","author":"MS Ardawi","year":"2012","unstructured":"Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA (2012) High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 27(12):2592\u20132602. https:\/\/doi.org\/10.1002\/jbmr.1718","journal-title":"J Bone Miner Res"},{"issue":"16","key":"1261_CR67","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"6","key":"1261_CR68","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39(6):1082\u20131090. https:\/\/doi.org\/10.1007\/s00774-021-01253-y","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"1261_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","volume":"19","author":"C Fixen","year":"2021","unstructured":"Fixen C, Tunoa J (2021) Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep 19(1):15\u201322. https:\/\/doi.org\/10.1007\/s11914-020-00652-w","journal-title":"Curr Osteoporos Rep"},{"issue":"11","key":"1261_CR70","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/ndt\/gfab053","volume":"37","author":"MA Podest\u00e0","year":"2022","unstructured":"Podest\u00e0 MA, Cucchiari D, Ciceri P, Messa P, Torregrosa JV, Cozzolino M (2022) Cardiovascular calcifications in kidney transplant recipients. Nephrol Dial Transplant 37(11):2063\u20132071. https:\/\/doi.org\/10.1093\/ndt\/gfab053","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1261_CR71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00223-013-9712-z","volume":"93","author":"M Wu","year":"2013","unstructured":"Wu M, Rementer C, Giachelli CM (2013) Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93(4):365\u2013373. https:\/\/doi.org\/10.1007\/s00223-013-9712-z","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"1261_CR72","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/joe-12-0143","volume":"214","author":"KA Staines","year":"2012","unstructured":"Staines KA, MacRae VE, Farquharson C (2012) The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214(3):241\u2013255. https:\/\/doi.org\/10.1530\/joe-12-0143","journal-title":"J Endocrinol"},{"key":"1261_CR73","doi-asserted-by":"publisher","first-page":"109458","DOI":"10.1016\/j.cellsig.2019.109458","volume":"66","author":"RA da Silva","year":"2020","unstructured":"da Silva RA, da Feltran SG, Do Fernandes CCJ, Zambuzzi WF (2020) Osteogenic gene markers are epigenetically reprogrammed during contractile-to-calcifying vascular smooth muscle cell phenotype transition. Cell Signal 66:109458. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109458","journal-title":"Cell Signal"},{"issue":"4","key":"1261_CR74","doi-asserted-by":"publisher","first-page":"E658","DOI":"10.1152\/ajpendo.00204.2019","volume":"317","author":"F Schinzari","year":"2019","unstructured":"Schinzari F, Tesauro M, Bertoli A, Valentini A, Veneziani A, Campia U, Cardillo C (2019) Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents. Am J Physiol Endocrinol Metab 317(4):E658\u2013E666. https:\/\/doi.org\/10.1152\/ajpendo.00204.2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1261_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413536","author":"R Villa-Bellosta","year":"2021","unstructured":"Villa-Bellosta R (2021) Vascular calcification: key roles of phosphate and pyrophosphate. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222413536","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1261_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.200","volume":"4","author":"W Pan","year":"2020","unstructured":"Pan W, Jie W (2020) Huang H (2023) Vascular calcification: molecular mechanisms and therapeutic interventions. MedComm 4(1):e200. https:\/\/doi.org\/10.1002\/mco2.200","journal-title":"MedComm"},{"issue":"3","key":"1261_CR77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/01.Atv.0000059406.92165.31","volume":"23","author":"KL Tyson","year":"2003","unstructured":"Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM (2003) Osteo\/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23(3):489\u2013494. https:\/\/doi.org\/10.1161\/01.Atv.0000059406.92165.31","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1261_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Mackenzie NC, Mill\u00e1n JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595. https:\/\/doi.org\/10.1371\/journal.pone.0019595","journal-title":"PLoS ONE"},{"issue":"2","key":"1261_CR79","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.156","volume":"88","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, D\u2019Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235\u2013240. https:\/\/doi.org\/10.1038\/ki.2015.156","journal-title":"Kidney Int"},{"issue":"2","key":"1261_CR80","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00774-018-0919-y","volume":"37","author":"SK Bisson","year":"2019","unstructured":"Bisson SK, Ung RV, Picard S, Valade D, Agharazii M, Larivi\u00e8re R, Mac-Way F (2019) High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats. J Bone Miner Metab 37(2):212\u2013223. https:\/\/doi.org\/10.1007\/s00774-018-0919-y","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"1261_CR81","doi-asserted-by":"publisher","first-page":"F753","DOI":"10.1152\/ajprenal.00528.2017","volume":"314","author":"A Nordholm","year":"2018","unstructured":"Nordholm A, Mace ML, Gravesen E, Hofman-Bang J, Morevati M, Olgaard K, Lewin E (2018) Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. Am J Physiol Ren Physiol 314(5):F753\u2013F762. https:\/\/doi.org\/10.1152\/ajprenal.00528.2017","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"1261_CR82","doi-asserted-by":"publisher","first-page":"F477","DOI":"10.1152\/ajprenal.00472.2015","volume":"310","author":"JL Rukov","year":"2016","unstructured":"Rukov JL, Gravesen E, Mace ML, Hofman-Bang J, Vinther J, Andersen CB, Lewin E, Olgaard K (2016) Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. Am J Physiol Ren Physiol 310(6):F477-491. https:\/\/doi.org\/10.1152\/ajprenal.00472.2015","journal-title":"Am J Physiol Ren Physiol"},{"key":"1261_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126467","author":"L Nguyen-Yamamoto","year":"2019","unstructured":"Nguyen-Yamamoto L, Tanaka KI, St-Arnaud R, Goltzman D (2019) Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.126467","journal-title":"JCI Insight"},{"issue":"3","key":"1261_CR84","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/atvbaha.116.308723","volume":"37","author":"SM Krishna","year":"2017","unstructured":"Krishna SM, Seto SW, Jose RJ, Li J, Morton SK, Biros E, Wang Y, Nsengiyumva V, Lindeman JH, Loots GG, Rush CM, Craig JM, Golledge J (2017) Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol 37(3):553\u2013566. https:\/\/doi.org\/10.1161\/atvbaha.116.308723","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1261_CR85","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D\u2019Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28(12):3024\u20133030. https:\/\/doi.org\/10.1093\/ndt\/gft039","journal-title":"Nephrol Dial Transplant"},{"key":"1261_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11070428","author":"A De Mar\u00e9","year":"2019","unstructured":"De Mar\u00e9 A, Maudsley S, Azmi A, Hendrickx JO, Opdebeeck B, Neven E, D\u2019Haese PC, Verhulst A (2019) Sclerostin as regulatory molecule in vascular media calcification and the bone\u2013vascular axis. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins11070428","journal-title":"Toxins (Basel)"},{"issue":"8","key":"1261_CR87","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1210\/jc.2013-1521","volume":"98","author":"KJ Claes","year":"2013","unstructured":"Claes KJ, Viaene L, Heye S, Meijers B, d\u2019Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221\u20133228. https:\/\/doi.org\/10.1210\/jc.2013-1521","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1261_CR88","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jbmr.4503","volume":"37","author":"A De Mar\u00e9","year":"2022","unstructured":"De Mar\u00e9 A, Opdebeeck B, Neven E, D\u2019Haese PC, Verhulst A (2022) Sclerostin protects against vascular calcification development in mice. J Bone Miner Res 37(4):687\u2013699","journal-title":"J Bone Miner Res"},{"key":"1261_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2013.10.019","volume":"59","author":"MM Roforth","year":"2014","unstructured":"Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1\u20136. https:\/\/doi.org\/10.1016\/j.bone.2013.10.019","journal-title":"Bone"},{"issue":"3","key":"1261_CR90","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jbmr.4203","volume":"36","author":"ML Mace","year":"2021","unstructured":"Mace ML, Gravesen E, Nordholm A, Egstrand S, Morevati M, Nielsen C, Kjaer A, Behets G, D\u2019Haese P, Olgaard K, Lewin E (2021) Chronic kidney disease-induced vascular calcification impairs bone metabolism. J Bone Miner Res 36(3):510\u2013522. https:\/\/doi.org\/10.1002\/jbmr.4203","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1261_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195928","volume":"13","author":"L Cheddani","year":"2018","unstructured":"Cheddani L, Radulescu C, Chaignon M, Karras A, Neuzillet Y, Duong JP, Tabibzadeh N, Letavernier E, Delahousse M, Haymann JP (2018) From arterial stiffness to kidney graft microvasculature: mortality and graft survival within a cohort of 220 kidney transplant recipients. PLoS ONE 13(5):e0195928. https:\/\/doi.org\/10.1371\/journal.pone.0195928","journal-title":"PLoS ONE"},{"issue":"8","key":"1261_CR92","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1097\/tp.0000000000000660","volume":"99","author":"DO Dahle","year":"2015","unstructured":"Dahle DO, Eide IA, \u00c5sberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstr\u00f8m H, Mj\u00f8en G, Hartmann A (2015) Aortic stiffness in a mortality risk calculator for kidney transplant recipients. Transplantation 99(8):1730\u20131737. https:\/\/doi.org\/10.1097\/tp.0000000000000660","journal-title":"Transplantation"},{"issue":"10","key":"1261_CR93","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/2047-783x-15-10-452","volume":"15","author":"A Mitchell","year":"2010","unstructured":"Mitchell A, Opazo Saez A, Kos M, Witzke O, Kribben A, N\u00fcrnberger J (2010) Pulse wave velocity predicts mortality in renal transplant patients. Eur J Med Res 15(10):452\u2013455. https:\/\/doi.org\/10.1186\/2047-783x-15-10-452","journal-title":"Eur J Med Res"},{"issue":"9","key":"1261_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139138","volume":"10","author":"HS Kim","year":"2015","unstructured":"Kim HS, Seung J, Lee JH, Chung BH, Yang CW (2015) Clinical significance of pre-transplant arterial stiffness and the impact of kidney transplantation on arterial stiffness. PLoS ONE 10(9):e0139138. https:\/\/doi.org\/10.1371\/journal.pone.0139138","journal-title":"PLoS ONE"},{"issue":"1","key":"1261_CR95","doi-asserted-by":"publisher","DOI":"10.15190\/d.2016.2","volume":"4","author":"SF Mause","year":"2016","unstructured":"Mause SF, Deck A, Hennies M, Kaesler N, Evenepoel P, Boisvert WA, Janssen U, Brandenburg VM (2016) Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. Discoveries (Craiova) 4(1):e55. https:\/\/doi.org\/10.15190\/d.2016.2","journal-title":"Discoveries (Craiova)"},{"issue":"5","key":"1261_CR96","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s11255-015-0971-7","volume":"47","author":"RM Moys\u00e9s","year":"2015","unstructured":"Moys\u00e9s RM, Jamal SA, Graciolli FG, dos Reis LM, Elias RM (2015) Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int Urol Nephrol 47(5):847\u2013850. https:\/\/doi.org\/10.1007\/s11255-015-0971-7","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"1261_CR97","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/ndt\/gfx282","volume":"33","author":"P Delanaye","year":"2018","unstructured":"Delanaye P, Paquot F, Bouquegneau A, Blocki F, Krzesinski JM, Evenepoel P, Pottel H, Cavalier E (2018) Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol Dial Transplant 33(8):1404\u20131410. https:\/\/doi.org\/10.1093\/ndt\/gfx282","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1261_CR98","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30(2):288\u2013293. https:\/\/doi.org\/10.1093\/ndt\/gfu301","journal-title":"Nephrol Dial Transplant"},{"key":"1261_CR99","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1471-2369-15-190","volume":"15","author":"FL Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves FL, Elias RM, dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moys\u00e9s RM (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190. https:\/\/doi.org\/10.1186\/1471-2369-15-190","journal-title":"BMC Nephrol"},{"issue":"1\u20132","key":"1261_CR100","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000366449","volume":"128","author":"P Delanaye","year":"2014","unstructured":"Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, M\u00e9dart L, Bruy\u00e8re O, Reginster JY, Pottel H, Cavalier E (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128(1\u20132):127\u2013134. https:\/\/doi.org\/10.1159\/000366449","journal-title":"Nephron Clin Pract"},{"issue":"12","key":"1261_CR101","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s11255-016-1387-8","volume":"48","author":"M Kanbay","year":"2016","unstructured":"Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, Covic A (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029\u20132042. https:\/\/doi.org\/10.1007\/s11255-016-1387-8","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"1261_CR102","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1074\/jbc.M705092200","volume":"283","author":"AG Robling","year":"2008","unstructured":"Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. J Biol Chem 283(9):5866\u20135875. https:\/\/doi.org\/10.1074\/jbc.M705092200","journal-title":"J Biol Chem"},{"key":"1261_CR103","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-2369-14-219","volume":"14","author":"VM Brandenburg","year":"2013","unstructured":"Brandenburg VM, Kramann R, Koos R, Kr\u00fcger T, Schurgers L, M\u00fchlenbruch G, H\u00fcbner S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219. https:\/\/doi.org\/10.1186\/1471-2369-14-219","journal-title":"BMC Nephrol"},{"issue":"6","key":"1261_CR104","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/ki.2015.194","volume":"88","author":"AR Qureshi","year":"2015","unstructured":"Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, S\u00f6derberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356\u20131364. https:\/\/doi.org\/10.1038\/ki.2015.194","journal-title":"Kidney Int"},{"key":"1261_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081660","author":"A Vestergaard Kvist","year":"2021","unstructured":"Vestergaard Kvist A, Faruque J, Vallejo-Yag\u00fce E, Weiler S, Winter EM, Burden AM (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. https:\/\/doi.org\/10.3390\/jcm10081660","journal-title":"J Clin Med"},{"issue":"16","key":"1261_CR106","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2217\/bmm-2021-0168","volume":"15","author":"O Mayer","year":"2021","unstructured":"Mayer O, Bruthans J, Seidlerov\u00e1 J, Gel\u017einsk\u00fd J, Ku\u010dera R, Karnosov\u00e1 P, Mate\u0159\u00e1nkov\u00e1 M, Rycheck\u00e1 M, Wohlfahrt P, C\u00edfkov\u00e1 R, Filipovsk\u00fd J, Vermeer C (2021) Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. Biomark Med 15(16):1465\u20131477. https:\/\/doi.org\/10.2217\/bmm-2021-0168","journal-title":"Biomark Med"},{"issue":"4","key":"1261_CR107","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/ckj\/sfaa069","volume":"14","author":"E Stavrinou","year":"2021","unstructured":"Stavrinou E, Sarafidis PA, Loutradis C, Memmos E, Faitatzidou D, Giamalis P, Koumaras C, Karagiannis A, Papagianni A (2021) Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study. Clin Kidney J 14(4):1165\u20131172","journal-title":"Clin Kidney J"},{"issue":"6","key":"1261_CR108","doi-asserted-by":"publisher","first-page":"48","DOI":"10.26442\/terarkh201890648-54","volume":"90","author":"LY Milovanova","year":"2018","unstructured":"Milovanova LY, Dobrosmyslov IA, Milovanov YS, Taranova MV, Kozlov VV, Milovanova SY, Kozevnikova EI (2018) Fibroblast growth factor-23 (FGF-23)\/soluble Klotho protein (sKlotho)\/sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration. Ter Arkh 90(6):48\u201354. https:\/\/doi.org\/10.26442\/terarkh201890648-54","journal-title":"Ter Arkh"},{"issue":"11","key":"1261_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207348","volume":"13","author":"K Mathold","year":"2018","unstructured":"Mathold K, Wanby P, Brudin L, Von SP, Carlsson M (2018) Alterations in bone turnover markers in patients with noncardio-embolic ischemic stroke. PLoS ONE 13(11):e0207348. https:\/\/doi.org\/10.1371\/journal.pone.0207348","journal-title":"PLoS ONE"},{"key":"1261_CR110","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2016.08.003","volume":"253","author":"XW He","year":"2016","unstructured":"He XW, Wang E, Bao YY, Wang F, Zhu M, Hu XF, Jin XP (2016) High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. Atherosclerosis 253:22\u201328. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.003","journal-title":"Atherosclerosis"},{"issue":"2","key":"1261_CR111","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00467-015-3069-7","volume":"31","author":"VM Brandenburg","year":"2016","unstructured":"Brandenburg VM, D\u2019Haese P, Deck A, Mekahli D, Meijers B, Neven E, Evenepoel P (2016) From skeletal to cardiovascular disease in 12 steps\u2014the evolution of sclerostin as a major player in CKD\u2013MBD. Pediatr Nephrol 31(2):195\u2013206. https:\/\/doi.org\/10.1007\/s00467-015-3069-7","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"1261_CR112","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.transproceed.2014.07.024","volume":"46","author":"P Tomei","year":"2014","unstructured":"Tomei P, Zaza G, Granata S, Gatti D, Fraccarollo C, Gesualdo L, Boschiero L, Lupo A (2014) Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients. Transplant Proc 46(7):2241\u20132246. https:\/\/doi.org\/10.1016\/j.transproceed.2014.07.024","journal-title":"Transplant Proc"},{"key":"1261_CR113","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673250291231121052433","author":"FMB Vigil","year":"2024","unstructured":"Vigil FMB, Vaz de Castro PAS, Hasparyk UG, Bartolomei VS, Silva A (2024) Potential role of bone metabolism markers in kidney transplant recipients. Curr Med Chem. https:\/\/doi.org\/10.2174\/0109298673250291231121052433","journal-title":"Curr Med Chem"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01261-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T10:03:11Z","timestamp":1726480991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01261-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":113,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01261-w","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Baris Afsar, Rengin Elsurer Afsar, Yasar Caliskan, and Krista L. Lentine declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}